We are committed to making a meaningful impact on patients' lives.

Our mission is to develop transformative medicines for orphan diseases of the kidney.

  • Life-threatening Genetic Disease
  • 4th Leading Cause of Kidney Failure
  • No Approved Drug Treatments in the US
  • Learn More
Please join Palladio Biosciences as we present the company and information about lixivaptan's development program for Autosomal Dominant Polycystic Kidney Disease during the Bio CEO & Investor Conference at the New York Marriott Marquis in New York City February 12-13, 2018.